Pfizer INC 10-Q quarterly reports

Pfizer Inc. reported a net loss for the second quarter of 2026, impacted by substantial intangible asset impairments and increased legal costs, though total revenues saw a modest increase.

Pfizer Inc. announced its first quarter 2026 financial results, showing a 5% increase in total revenues to $14.5 billion, driven by strong performance in key biopharmaceutical products.

Pfizer reported a 6% revenue decrease in Q3 2025, primarily due to lower demand for COVID-19 products, while advancing strategic cost-cutting and a major acquisition bid for Metsera.

Pfizer reported a significant increase in second-quarter net income and EPS, driven by strong product performance and ongoing cost realignment efforts, despite headwinds from the IRA Medicare Part D Redesign.

Pfizer's Q1 2025 revenues decreased by 8% due to lower sales of COVID-19 products and the impact of the Inflation Reduction Act, despite growth in other key products.

Pfizer's third-quarter earnings surged, fueled by robust sales of Paxlovid and contributions from the recently acquired Seagen, despite some declines in other key products.

Pfizer's second quarter results show a slight revenue increase but a significant drop in income due to restructuring costs and other factors, as the company navigates strategic changes.

Pfizer's first-quarter 2024 revenue declined by 20% year-over-year, primarily due to decreased sales of COVID-19 products, though oncology and other key areas showed growth.